UPDATE: Hearing Positive Chatter Circulating in Anadys Pharma on Upcoming Phase II Results

@BioRunUp posts "$ANDS Poised for Rebound, Run-Up into Phase 2 Results for Pair of HCV Drugs" Also, @ProphetAlerts writes "$ANDS rippp ... catalysts coming for this bad boy. 6 months ago it went from .90 to $1.50 in a few days." Anadys Pharmaceuticals ANDS, on December 1st, announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling patients in a Phase Ib study evaluating ANA598 for the treatment of patients chronically infected with HCV.